The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntertek Group Regulatory News (ITRK)

Share Price Information for Intertek Group (ITRK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,956.00
Bid: 4,968.00
Ask: 4,970.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.04%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 4,956.00
ITRK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

22 Nov 2016 07:00

RNS Number : 7630P
Intertek Group PLC
22 November 2016
 

 

For a printer friendly version of this announcement, please click on the link below: -

http://www.rns-pdf.londonstockexchange.com/rns/7630P_-2016-11-21.pdf

 

 

 

TRADING STATEMENT

22 NOVEMBER 2016

 

Intertek Group plc ("Intertek" or "the Group"), a leading Total Quality Assurance provider to industries worldwide, today releases its Trading Statement for the period from 1 January to 31 October 2016 ("period"). All comparative comments in this statement reflect comparisons with the corresponding period during 2015. The Group's full year results to 31 December 2016 will be announced on 7 March 2017.

 

On track to deliver robust earnings growth in 2016

 

Strong revenue growth: +10% at constant rates, +18% at actual rates

 

High revenue growth in the high margin Products division: +22% at constant rates, +33% at actual rates

 

Recent acquisitions contributed £200m of additional revenues

 

Stable organic revenue growth at constant rates: Products +5.5%, Trade +1%, Resources -13%

 

On track to deliver 2016 target of robust revenue growth at constant rates with stable margin

 

 

André Lacroix: Chief Executive Officer Statement

 

"In the first ten months, the Group has delivered 10% revenue growth at constant rates and is on track to deliver robust revenue growth, with strong operational discipline, stable margin and good cash generation in 2016.

 

The Products and Trade related divisions, which represent over 90% of the Group's earnings, delivered an excellent performance with good organic growth of 4% at constant rates. However, trading conditions remain, as expected, challenging in the Resource related division. The acquisitions made since January 2015 are performing well and contributed £200m of additional revenues.

 

The $250bn global quality assurance industry has attractive structural growth prospects driven by an increased focus of corporations on risk management, global trade flows, global demand for energy, expanding regulations, more complex sourcing and distribution operations, technological innovations, government investments in large infrastructure projects, and increased consumer demand for higher quality and more sustainable products.

We operate a high quality and highly cash generative earnings model and we are uniquely positioned to seize these exciting growth opportunities with our Total Quality value proposition that provides a superior service, offering global Assurance, Testing, Inspection and Certification solutions to our customers across multiple industries delivered in our global network of over 1,000 state of the art facilities in over 100 countries.

Our differentiated Total Quality Assurance growth strategy will move the centre of gravity of our portfolio towards the attractive growth and margin opportunities in the industry based on a disciplined approach to revenue, margin, portfolio and cash performance management, with a disciplined capital allocation to deliver attractive returns for our shareholders."

 

Revenue Performance

 

10 months - January to October

4 months - July to October

2016

2015

Change at actual

Change at

constant

2016

2015

Change at actual

Change at

constant

Group

Revenue

£2,097.7m

£1,779.5m

17.9%

9.9%

£893.8m

£719.3m

24.3%

9.0%

Organic revenue

£1,896.7m

£1,769.0m

7.2%

0.0%

£805.9m

£711.6m

13.3%

(0.7%)

Revenue from acquisitions

£201.0m

£10.5m

£87.9m

£7.7m

Products

Revenue

£1,193.8m

£901.1m

32.5%

22.1%

£515.8m

£369.4m

39.7%

21.8%

Organic revenue

£1,026.8m

£896.6m

14.5%

5.5%

£441.6m

£364.9m

21.0%

5.5%

Trade

Revenue

£474.3m

£445.1m

6.5%

0.9%

£201.8m

£177.8m

13.5%

0.7%

Organic revenue

£474.3m

£445.1m

6.5%

0.9%

£201.8m

£177.8m

13.5%

0.7%

Resources

Revenue

£429.6m

£433.3m

(0.8%)

(6.8%)

£176.2m

£172.1m

2.4%

(10.2%)

Organic revenue

£395.6m

£427.3m

(7.4%)

(12.9%)

£162.5m

£168.9m

(3.8%)

(15.5%)

 

 

 

Products Divisional Review

 

Our Product related businesses delivered an excellent revenue performance with a growth of 22%, driven by robust organic growth of 5.5% at constant rates and the contribution from acquisitions.

· Our Softlines business delivered robust organic growth, benefiting from our clients' supply chain expansion in Vietnam, Cambodia and India as well as a strong performance in the footwear sector;

· Our Hardline and Toy business continues to take advantage of our strong global account relationships and delivered robust organic growth performance;

· In our Transportation Technologies business, we capitalised on our clients' investments in new powertrains and delivered double-digit organic growth;

· Our Business Assurance business delivered double-digit organic growth, benefiting from the increased focus of corporations on risk management;

· We delivered solid organic growth in our Electrical & Wireless business, driven by higher regulatory standards in energy efficiency;

· We continue to benefit from the increased focus of corporations on food safety that saw our Food business deliver good organic growth;

· Our Chemicals & Pharma business contributed solid organic growth performance as we continue to leverage the structural growth opportunities in healthcare; and

· Our Building & Construction business benefited from the acquisitions of PSI and MT Group in the USA and delivered robust organic growth, driven by the growing demand for greener and higher quality buildings in the USA as well as significant wins in large infrastructure projects.

The full year outlook for our Products division remains unchanged and we continue to expect to deliver robust organic growth as well as seeing the benefit of acquisitions.

 

Trade Divisional Review

 

Our Trade related businesses delivered solid organic growth of 1% at constant rates.

· Benefiting from structural growth drivers, our Cargo/AA business reported solid organic growth performance;

· Lower trade volume activities in the Middle East and Africa resulted in reduced demand for our Government and Trade Services compared to the same period last year; and

· Our Agriculture business continued to benefit from the expansion of the supply chain of our clients in fast growing markets to deliver robust organic growth performance.

The full year outlook for our Trade division remains unchanged and we continue to expect to deliver solid organic growth.

 

Resources Divisional Review

 

Our Resource related businesses faced, as expected, challenging trading conditions and saw an organic revenue decline of 13% at constant rates.

· Demand for Capex inspection services was impacted by lower investments and reduced exploration activities by our clients;

· The demand for Opex maintenance services remained stable; and

· Testing activities in the Minerals business are stable.

The full year outlook for our Resources Division remains unchanged: we do not believe we have reached the trough in the Capex inspection services end market and we expect the trading conditions to remain challenging.

 

Strategy and M&A

 

We have started the roll out of our differentiated growth strategy outlined earlier this year and we are pleased with the progress we have made.

Our 5x5 growth strategy will move the centre of gravity of the Group towards the attractive growth and margin areas in the $250bn Quality Assurance market.

At the heart of our 5x5 growth strategy is our Total Quality Assurance value proposition that provides a superior customer service to our clients based on our industry leading Assurance, Testing, Inspection and Certification solutions.

Intertek is well positioned to seize the attractive external growth opportunities in a very fragmented industry and we continue to make progress with our M&A strategy.

· In January 2016, we completed the acquisition of FIT Italia, an Italian company providing food testing and assurance services to the retail and agricultural sectors;

· In October 2016, we completed the acquisition of EWA Canada, a leading cyber security assurance business providing solutions to a broad range of industries; and

· In November 2016, we announced the formation of a joint venture with ABC Analitic to create a market leading environmental quality assurance business and take the #1 position in Mexico's fast growing environmental market.

 

Investment & Financial Position

 

Our year end net debt guidance of £770-820m, assuming no further acquisitions and no significant forex changes, remains unchanged.

 

Outlook

 

The Group remains on track to deliver its 2016 target of robust revenue growth at constant currency with stable margin and strong cash generation. We will continue to benefit from the acquisitions made since January 2015 and we expect organic growth to be stable at constant currency.

 

We expect our Product related businesses to deliver robust organic growth, our Trade related businesses to report solid organic growth performance, while the market conditions will remain challenging in our Resource related businesses.

 

Looking further ahead, the global Quality Assurance market will benefit from exciting growth prospects driven by an increased focus of corporations on risk management, global trade flows, global demand for energy, expanding regulations, more complex sourcing and distribution operations, technological innovations, government investments in large infrastructure projects, and increased consumer demand for higher quality and more sustainable products.

 

We provide our customers with a Total Quality Assurance differentiated value proposition based on the depth and breadth of our technical expertise, our global network of over 1,000 state of the art facilities in over 100 countries, our industry leading Assurance, Testing, Inspection and Certification solutions, and our customer centric culture.

 

We continue to be uniquely positioned to benefit from the GDP+ organic growth prospects in the Quality Assurance Industry in the medium to long term, leveraging our high quality and highly cash generative earnings model.

 

 

-ENDS-

 

 

Contacts

For further information, please contact

 

Josh Egan, Investor Relations Director

Telephone: +44 (0) 20 7396 3400 investor@intertek.com

 

Jonathon Brill, Oliver Winters, FTI Consulting

Telephone: +44 (0) 20 3727 1000 intertek@fticonsulting.com

 

Analysts' Call

A live audiocast for analysts and investors will be held today at 8.00am. Details can be found at http://www.intertek.com/investors/ together with a pdf copy of this report. A recording of the audiocast will be available later in the day.

 

About Intertek

 

Intertek is a leading Total Quality Assurance provider to industries worldwide. Our network of more than 1,000 laboratories and offices and over 40,000 people in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers' operations and supply chains.

 

www.intertek.com

 

Bringing quality and safety to life

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBFLLLQFFXFBK
Date   Source Headline
22nd Mar 20249:00 amRNSAnnual Financial Report
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
14th Mar 20241:00 pmRNSDirector/PDMR Shareholding
13th Mar 20241:00 pmRNSDirector/PDMR Shareholding
5th Mar 20247:00 amRNSFinal Results
4th Mar 20247:00 amRNSAcquisition
1st Mar 20241:00 pmRNSDirectorate Change
28th Feb 20241:00 pmRNSDirector/PDMR Shareholding
23rd Nov 20237:00 amRNSTrading Statement
22nd Nov 20231:00 pmRNSBlock listing Interim Review
14th Sep 20231:00 pmRNSDirector Declaration
24th Aug 20237:00 amRNSAcquisition
28th Jul 20237:00 amRNSHalf-year Report
12th Jul 202310:00 amRNSDirectorate Change
7th Jun 20231:00 pmRNSDirector/PDMR Shareholding
31st May 20231:00 pmRNSDirector/PDMR Shareholding
30th May 20233:00 pmRNSHolding(s) in Company
30th May 20231:00 pmRNSBlock listing Interim Review
24th May 202311:00 amRNSResult of AGM
24th May 20237:00 amRNSTrading Statement
3rd May 20237:00 amRNSCapital Markets Event
27th Apr 20234:00 pmRNSDirector Declaration
26th Apr 20234:30 pmRNSDirector Declaration
20th Apr 20234:00 pmRNSDirector Declaration
3rd Apr 20237:00 amRNSAcquisition
24th Mar 20239:00 amRNSNotice of 2023 AGM
21st Mar 20239:00 amRNSAnnual Financial Report
20th Mar 20237:00 amRNSDirectorate Change
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
14th Mar 20233:00 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNSFinal Results
23rd Dec 202210:00 amRNSDirectorate Change
13th Dec 202211:00 amRNSDirector Declaration
12th Dec 20221:00 pmRNSDirector Declaration
24th Nov 20227:00 amRNSTrading Statement
21st Nov 20221:00 pmRNSBlock listing Interim Review
2nd Aug 20229:00 amRNSDirector/PDMR Shareholding
29th Jul 20227:01 amRNSAcquisition
29th Jul 20227:00 amRNSHalf-year Report
21st Jun 20221:00 pmRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSDirectorate Change
25th May 202211:00 amRNSResult of AGM
25th May 20227:00 amRNSTrading Statement
23rd May 20221:00 pmRNSBlock listing Interim Review
4th Apr 20223:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20221:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20221:00 pmRNSDirector/PDMR Shareholding
18th Mar 20229:00 amRNSAnnual Financial Report
14th Mar 20221:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.